000403 派林生物
按盤價 
24.770 +1.950 (+8.545%)
24.770 +1.950 (+8.545%) | 2024/06 - 中期 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | 4.347 | 8.563 | 8.901 | 10.727 | 21.070 |
| 總資產報酬率 ROA (%) | 3.744 | 7.369 | 7.792 | 8.921 | 12.719 |
| 投入資產回報率 ROIC (%) | 4.029 | 7.999 | 8.489 | 9.918 | 13.801 | 邊際利潤分析 |
| 銷售毛利率 (%) | 50.197 | 51.481 | 52.127 | 46.072 | 48.820 |
| 營業利潤率 (%) | 33.665 | 29.853 | 27.583 | 23.351 | 20.982 |
| 息稅前利潤/營業總收入 (%) | 30.444 | 27.077 | 25.157 | 20.907 | 20.788 |
| 淨利潤/營業總收入 (%) | 28.779 | 26.258 | 24.434 | 19.858 | 17.399 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 98.167 | 100.163 | 98.707 | 105.739 | 99.987 |
| 價值變動淨收益/利潤總額(%) | 2.878 | -1.681 | 1.206 | 17.010 | 0.000 |
| 營業外收支淨額/利潤總額(%) | -3.140 | -1.029 | -0.460 | -0.528 | -1.429 | 償債能力分析 |
| 流動比率 (X) | 3.716 | 3.715 | 3.176 | 3.845 | 1.352 |
| 速動比率 (X) | 2.478 | 2.729 | 2.526 | 2.694 | 0.668 |
| 資產負債率 (%) | 13.892 | 14.004 | 14.046 | 10.724 | 42.437 |
| 帶息債務/全部投入資本 (%) | 6.481 | 5.987 | 4.511 | 1.270 | -- |
| 股東權益/帶息債務 (%) | 1,427.023 | 1,551.423 | 2,083.639 | 7,632.613 | 278.228 |
| 股東權益/負債合計 (%) | 620.383 | 614.644 | 612.517 | 832.250 | 135.422 |
| 利息保障倍數 (X) | -13.861 | -10.952 | -10.939 | -9.005 | 204.113 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 86.904 | 109.718 | 102.622 | 74.207 | 0.000 |
| 存貨周轉天數 (天) | 325.900 | 244.231 | 213.018 | 199.877 | 0.000 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 30/09/2024 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
